12 December 2016 : Laboratory Research
Inhibition of Cervical Cancer by Promoting IGFBP7 Expression Using Ellagic Acid from Pomegranate PeelHongjun Guo1ABCDEFG, Dongya Zhang1CDE*, Qingrui Fu1BF
Med Sci Monit 2016; 22:4881-4886
BACKGROUND: The aim of this study was to explore the mechanism by which cervical cancer is inhibited by promoting IGFBP7 expression using ellagic acid from pomegranate peel extract.
MATERIAL AND METHODS: HeLa cells were divided into 6 groups: control group (NC), blank control group (BL), and IGFBP7 overexpression group (IGFBP7), and 2.5 uM, 5. 0 uM, and 10.0 uM ellagic acid-treated groups. The cell proliferation ability was detected and the degree of invasion in the 6 groups was measured by Transwell assay. The expression levels of IGFBP7 and AKT/mTOR in the 6 groups of cells were detected by RT-PCR technique.
RESULTS: Compared with NC and BL groups, The IGFBP7 gene expressions of the IGFPB7 and ellagic acid-treated groups were significantly increased (P<0.05). There was a dose-effect dependence in the ellagic acid-treated groups. The invasion ability of the IGFBP7 group and ellagic acid-treated groups was significantly lower than that of NC and BL groups in HeLa cells (P<0.05). The apoptosis rate of the IGFBP7 group and ellagic acid-treated groups was significantly higher than that of the NC and BL groups in HeLa cells (P<0.05). AKT and mTOR mRNA and protein expressions of the IGFBP7 group and ellagic acid-treated groups were significantly lower than that of the NC and BL groups (P<0.05). There was a dose-effect dependence in the ellagic acid-treated groups.
CONCLUSIONS: The ellagic acid in pomegranate peel extract can inhibit the AKT/mTOR signaling pathway by enhancing the expression level of IGFBP7, which can inhibit the HeLa cells in cervical cancer.
Keywords: Cell Proliferation - drug effects, Apoptosis - drug effects, Ellagic Acid - pharmacology, Hela Cells, Insulin-Like Growth Factor Binding Proteins - biosynthesis, Plant Extracts - pharmacology, Punicaceae - chemistry, Signal Transduction - drug effects, Uterine Cervical Neoplasms - prevention & control
This Week Editorial
20 September 2021 : EditorialEditorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19
Med Sci Monit 2021; 27:e934766
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
16 July 2021 : Review articleSilent Hypoxemia in Patients with COVID-19 Pneumonia: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.930776
09 July 2021 : Database AnalysisA Simple Clinical Prediction Tool for COVID-19 in Primary Care with Epidemiology: Temperature-Leukocytes-CT...
Med Sci Monit In Press; DOI: 10.12659/MSM.931467
20 Sep 2021 : Clinical ResearchComparison of the Use of Magnetic Resonance Imaging of Partial Anterior Cruciate Ligament Tears Using Maxim...
Med Sci Monit In Press; DOI: 10.12659/MSM.932228
20 Sep 2021 : Clinical ResearchAutomated Boluses and Delayed-Start Timers Prolong Perineural Local Anesthetic Infusions and Analgesia Foll...
Med Sci Monit In Press; DOI: 10.12659/MSM.933190
16 Sep 2021 : Clinical ResearchA Retrospective Evaluation of Operative and Postoperative Outcomes in Patients with Spinal Metastases from ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932995
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700